logo-loader

ANGLE aims for FDA approval of Parsortix in third quarter following successful meeting

Published: 03:10 22 Jan 2020 EST

ANGLE PLC - ANGLE aims for third quarter FDA approval of Parsortix following successful meeting
Parsortix is designed to detect cancer cells in the bloodstream

ANGLE PLC (LON:AGL) has predicted that it will receive regulatory clearance for its Parsortix cancer test by the third quarter of this year following a successful face-to-face meeting with the US Food and Drug Administration (FDA).

The AIM-listed firm said it is now preparing for a full De Novo submission to the FDA, a process that allows the regulator to approve medical devices that have no comparative already on the market.

WATCH: ANGLE aiming for FDA approval of Parsortix in third quarter

Parsortix is a blood test designed to help doctors detect signs of cancer at an early stage, offering a less invasive alternative to tissue biopsies currently used in hospitals.

ANGLE said it is aiming to file its De Novo submission in the first quarter of 2020, with the prospect of regulatory clearance by the third quarter.

While the FDA had requested additional analytical study work, the company said this will be undertaken in parallel with its drafting for the De Novo submission and will not impact the overall timescale of the process.

“We believe that FDA regulatory clearance, considered the gold standard for approval of medical diagnostic systems globally, would further competitively differentiate our Parsortix liquid biopsy system and should lead to an acceleration in commercial adoption of the system in both research and clinical settings", said ANGLE chief executive Andrew Newland.

In a note, analysts at house broker finnCap, which peg the company with a 115p target price, said the successful meeting had “significantly de-risked the regulatory path” for ANGLE, predicting that FDA clearance will be “a watershed moment” that will catalyse more commercialisation and partnership deals.

The shares surged 9.2% to 69p in early trading on Wednesday.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

14 hours, 26 minutes ago